Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MPI | P34949 | 1/20 | 0.40 |
| ▸ | TOP1 | P11387 | 2/20 | 0.39 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | PAK4 | O96013 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.37 |
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | IGF1R | P08069 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14581511 | 0.94 | CYP11B1 (0.45) | CYP11B1MEN1KMT2AMAPTHPGD | |
| SCHEMBL14581513 | 0.92 | ALDH1A1 (0.43) | CYP11B1MEN1KMT2AMAPTHPGD | |
| SCHEMBL29396258 | 0.90 | CYP11B1 (0.56) | CYP11B1MEN1KMT2AMAPTHPGD | |
| SCHEMBL346901 | 0.90 | CYP11B1 (0.56) | CYP11B1MEN1KMT2AMAPTHPGD | |
| SCHEMBL14581508 | 0.90 | PIK3CA (0.45) | CYP11B1MEN1KMT2AMAPTHPGD | |
| SCHEMBL14581509 | 0.89 | CYP11B1 (0.40) | CYP11B1MEN1KMT2AMAPTHPGD | |
| SCHEMBL14581510 | 0.87 | ALDH1A1 (0.44) | CYP11B1MEN1KMT2AMAPTHPGD | |
| SCHEMBL14581506 | 0.87 | TOP1 (0.42) | TOP1TOP2AIKBKBCHUKDAPK3 | |
| SCHEMBL13458897 | 0.87 | CYP11B1 (0.53) | CYP11B1MEN1KMT2AMAPTHPGD | |
| SCHEMBL13049747 | 0.87 | CYP11B1 (0.53) | CYP11B1MEN1KMT2AMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113563379-B | Semiconductor material comprising a phosphine oxide matrix and a metal salt | 诺瓦尔德股份有限公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-111900255-B | Organic light emitting device comprising a polar matrix, a metal dopant and a silver cathode | 诺瓦尔德股份有限公司 | 2024-03-15 | — | — | CN | disclosed |
| CN-108292706-B | Metal layer comprising alkali metal and second metal | 诺瓦尔德股份有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230025460-A1 | Light-Emitting Device and Light-Emitting Apparatus | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2023-01-26 | — | — | US | disclosed |
| US-20220285629-A1 | MIXED MATERIAL | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2022-09-08 | — | — | US | disclosed |
| US-11355721-B2 | Organic light emitting device comprising polar matrix, metal dopant and silver cathode | NOVALED GMBH (DE) | 2022-06-07 | — | — | US | disclosed |
| CN-113563379-A | Semiconductor material comprising a phosphine oxide matrix and a metal salt | 诺瓦尔德股份有限公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20210202842-A1 | N-Doped Semiconducting Material Comprising Phosphine Oxide Matrix and Metal Dopant | NOVALED GMBH (DE) | 2021-07-01 | — | — | US | disclosed |
| US-10941168-B2 | Phosphepine matrix compound for a semiconducting material | NOVALED GMBH (DE) | 2021-03-09 | — | — | US | disclosed |
| CN-107434813-B | Display device | 诺瓦尔德股份有限公司 | 2021-02-02 | — | — | CN | disclosed |
| US-20160211455-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | NOVALED GMBH (DE) | 2016-07-21 | — | — | US | disclosed |
| US-20150115241-A1 | Use of a Semiconducting Compound in an Organic Light Emitting Device | NOVALED GMBH (DE) | 2015-04-30 | — | — | US | disclosed |
| US-8475686-B2 | Bridged pyridoquinazoline or phenanthroline compounds and organic semiconducting material comprising that compound | NOVALED AG (DE) | 2013-07-02 | — | — | US | disclosed |
| CN-102986050-A | Electronic device comprising an organic semiconducting material | NOVALED AG | 2013-03-20 | — | — | CN | disclosed |
| EP-2367215-A1 | An organic photoactive device | Novaled AG (DE) | 2011-09-21 | — | — | EP | disclosed |
| WO-2011063927-A1 | ORGANIC ELECTRONIC DEVICE COMPRISING AN ORGANIC SEMICONDUCTING MATERIAL | NOVALED AG (DE) | 2011-06-03 | — | — | WO | disclosed |
| EP-2312663-A1 | Organic electronic device comprising an organic semiconducting material | Novaled AG (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20070037983-A1 | Phenanthroline derivative compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2007-02-15 | — | — | US | disclosed |
| US-20070037983-A1 | Phenanthroline derivative compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2007-02-15 | — | — | US | disclosed |
| US-20070037983-A1 | Phenanthroline derivative compound | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941168-B2 | Phosphepine matrix compound for a semiconducting material | PHOSPHO1, PSPH, PNMT | CYP11B1 4826/4885MEN1 8/4885KMT2A 549/4885 |
| US-20070037983-A1 | Phenanthroline derivative compound | POP1, PABPC1, NAP1L1 | CYP11B1 873/4885MEN1 3391/4885KMT2A 3592/4885 |
| US-20230025460-A1 | Light-Emitting Device and Light-Emitting Apparatus | MAP1LC3C, TCP1, TTC14 | CYP11B1 1858/4885MEN1 3771/4885KMT2A 2400/4885 |
| US-20220285629-A1 | MIXED MATERIAL | SLC11A2, ABCC1, GMNN | CYP11B1 774/4885MEN1 268/4885KMT2A 1690/4885 |
| US-20210202842-A1 | N-Doped Semiconducting Material Comprising Phosphine Oxide Matrix and Metal Dopant | NNMT, PNN, PNMT | CYP11B1 4407/4885MEN1 230/4885KMT2A 1774/4885 |
| US-20150115241-A1 | Use of a Semiconducting Compound in an Organic Light Emitting Device | SLC18A3, XPOT, SLC18A2 | CYP11B1 254/4885MEN1 1942/4885KMT2A 4478/4885 |
| US-20160211455-A1 | Semiconducting Material Comprising a Phosphine Oxide Matrix and Metal Salt | PSPH, STMN1, STMN2 | CYP11B1 4524/4885MEN1 282/4885KMT2A 973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.